Amar U. Kishan, MD

Articles

Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT

February 12th 2025

"For the MIRAGE trial specifically, we're going to continue following patients and we'll look at [data at] 5 years as well," says Amar U. Kishan, MD.

Amar Kishan, MD, on implications of MIRAGE trial data

Amar U. Kishan, MD

February 6th 2025

“I would say both there could be an increase in MRI-guided [SBRT] and there may be increase in investigation into shrinking margins with CT-guided SBRT as well,” says Amar U. Kishan, MD.

Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT

Amar U. Kishan, MD

February 1st 2025

"Physician scored GU toxicity grade 2 or greater at 2 years was 51% with the CT-guided and 27% with the MRI-guided," says Amar U. Kishan, MD.

Amar Kishan, MD, outlines the rationale for the MIRAGE trial

Amar U. Kishan, MD

January 29th 2025

“The trial was specifically looking at whether that aggressive margin reduction from 4 mm to 2 mm would lead to a reduction in physician-reported urinary toxicity, specifically in the first 90 days after radiation,” says Amar U. Kishan, MD.

Clinical Insights on Optimal Perirectal Spacing

Amar U. Kishan, MD

September 11th 2023

In the third article of this series, Amar U. Kishan, MD, provides clinical insights on the use of perirectal spacers for patients who receive hypofractionated radiation or SBRT.

Examining Optimal Perirectal Spacing

Amar U. Kishan, MD

August 28th 2023

In the third installment of this series, Amar U. Kishan, MD, discusses clinical factors to consider in the use of perirectal spacing for patients receiving hypofractionation or SBRT, and outlines unmet needs.